GlobeNewswire·Sep 17, 2026, 4:05 PM ET

Beta Bionics Announces Closing of $172.5 Million Public Offering of Common Stock

Beta Bionics, Inc. (NASDAQ: BBNX) closed a public offering of 7,652,175 common stock shares at $17.25 per share.
The company issued 1,043,484 pre-funded warrants to certain investors at $17.2499 per share instead of common stock shares.
Underwriters exercised their option in full to purchase an additional 1,304,348 shares of common stock.
Aggregate gross proceeds from the offering, including the option exercise, totaled $172.5 million before expenses.
Net proceeds will be used for general corporate purposes, including Mint™ commercialization, manufacturing expansion, research & development, product enhancements, strategic opportunities, & working capital.
J.P. Morgan, Piper Sandler, Wells Fargo Securities, & Leerink Partners served as joint book-running managers for the offering.
The offering was conducted pursuant to a Form S-3 shelf registration statement filed with the SEC on February 24, 2026.
A final prospectus supplement related to the offering has been filed with the SEC & is available on the SEC's website.